Status:
RECRUITING
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
Lead Sponsor:
Fox Chase Cancer Center
Conditions:
Renal Cell Carcinoma
Urothelial Carcinoma
Eligibility:
All Genders
Brief Summary
This is a comparative study using resected/ biopsied tumors samples collected from renal cell carcinoma and urothelial carcinoma patients who underwent surgical removal of lesions, followed by immune ...
Eligibility Criteria
Inclusion
- Eligible patients will include retrospectively identified patients with RCC or UC who have received treatment with ICB and achieved clinical benefit but subsequently developed a solitary new/progressive lesion that was removed surgically. Patients with other tumor types who otherwise meet criteria may be included at a later time
- Additionally, a group of patients with RCC who have undergone a metastasectomy but who did not receive treatment with ICB will be identified. These patients may be approached for study participation to serve as a comparator group
Exclusion
- \-
Key Trial Info
Start Date :
November 27 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT03291028
Start Date
November 27 2017
End Date
December 1 2025
Last Update
January 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fox Chase Cancer Center - Philadelphia
Philadelphia, Pennsylvania, United States, 19111-2497